DIDA INC-PF (02559): Public float expected to be restored by the end of May 2027
DIDA INC-PF (02559) announced that as of the date of this announcement, the Company's public float is approximately 11.26%, which remains below the minimum public float requirement under Rule 13.32B of the Listing Rules. As the Company's public float remains below 15% and the market value of shares held by the public is less than HK$500 million, the Company is subject to a serious public float deficiency as defined under Rule 13.32F of the Listing Rules.
DIDA INC-PF (02559) announces that, as at the date of this announcement, the Company's public float is approximately 11.26%, which remains below the minimum public float requirement under Rule 13.32B of the Listing Rules. As the Company's public float remains below 15% and the market capitalization of shares held by the public is less than HK$500 million, the Company has a serious public float deficiency as defined under Rule 13.32F of the Listing Rules.
The Company continues to consider measures to restore its public float. As at the date of this announcement, there have been no material developments in such measures. The Company currently expects to restore its public float and regain compliance with Rule 13.32B of the Listing Rules by the end of May 2027.
Related Articles

ANTENGENE-B (06996) repurchased 133,000 shares on October 21 for HK$404,900.

SHOUCHENG (00697) repurchased 1.5 million shares for HK$1.8788 million on October 21.

DAWNRAYS PHARMA (02348) repurchased 176,000 shares on October 21 for HKD 164,800.
ANTENGENE-B (06996) repurchased 133,000 shares on October 21 for HK$404,900.

SHOUCHENG (00697) repurchased 1.5 million shares for HK$1.8788 million on October 21.

DAWNRAYS PHARMA (02348) repurchased 176,000 shares on October 21 for HKD 164,800.






